CDK5R1 Gene

Migration, Crosslink

📖

CDK5R1 Gene

active

wiki page Created: 2026-04-02T07:19:19 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cdk5r1

📖 Wiki Page

gene1903 wordssynced 2026-04-02

CDK5R1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CDK5R1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CDK5R1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CDK5R1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CDK5R1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CDK5R1 encodes p35, the primary neuronal-specific regulatory subunit of cyclin-dependent kinase 5 (CDK5). The p35/CDK5 complex is a critical kinase in the central nervous system (CNS), regulating neuronal development, synaptic plasticity, and various cellular functions essential for cognitive function. Dysregulation of the p35/CDK5 pathway, particularly through proteolytic cleavage of p35 to the truncated p25 fragment, has emerged as a key mechanism in the pathogenesis of several neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). [@cdk2004] [@generation2004]

...

CDK5R1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CDK5R1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CDK5R1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CDK5R1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CDK5R1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CDK5R1 encodes p35, the primary neuronal-specific regulatory subunit of cyclin-dependent kinase 5 (CDK5). The p35/CDK5 complex is a critical kinase in the central nervous system (CNS), regulating neuronal development, synaptic plasticity, and various cellular functions essential for cognitive function. Dysregulation of the p35/CDK5 pathway, particularly through proteolytic cleavage of p35 to the truncated p25 fragment, has emerged as a key mechanism in the pathogenesis of several neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). [@cdk2004] [@generation2004]

The cleavage of p35 to p25 represents a critical switch that converts the physiological p35/CDK5 complex into a hyperactive p25/CDK5 complex. This conversion leads to aberrant phosphorylation of CDK5 substrates, including [tau protein](/proteins/tau), resulting in neurofibrillary tangle formation, synaptic dysfunction, and ultimately, neuronal death. Understanding the mechanisms governing p35 regulation and p25 generation has become a major focus for developing disease-modifying therapies for neurodegenerative conditions. [@generation2004] [@chen2018]

Gene And Protein Context

Symbol: CDK5R1
Full name: Cyclin-Dependent Kinase 5 Regulatory Subunit 1
Chromosomal locus: 17q11.2
NCBI Gene ID: [8851](https://www.ncbi.nlm.nih.gov/gene/8851)
Ensembl ID: [ENSG00000108395](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108395)
UniProt ID: [Q15078](https://www.uniprot.org/uniprot/Q15078)
Protein molecular weight: ~35 kDa (p35), 25 kDa (p25)
Expression: Neuron-specific; high expression in cortex, hippocampus, cerebellum, basal ganglia

The p35 protein (350 amino acids) is synthesized in neurons and localizes primarily to the plasma membrane through an N-terminal myristoylation site. This membrane association is important for the spatial regulation of CDK5 activity within neurons. The protein contains a CDK5-binding domain in its C-terminal region that is necessary for kinase activation. Upon proteolytic cleavage by calcium-activated calpains, p35 is cleaved to generate p25 (residues 98-307) and a p10 fragment (residues 1-98). The p25 fragment lacks the myristoylation site, leading to its accumulation in the cytosol and prolonged activation of CDK5. [@generation2004] [@chen2018]

Molecular Functions In The Nervous System

CDK5 Activation and Regulation

p35 serves as the essential neuronal activator of CDK5, a proline-directed serine/threonine kinase. Unlike other cyclin-dependent kinases, CDK5 does not require canonical cyclin binding for activation; instead, it is activated by binding to p35 (or the related p39 protein encoded by CDK5R2). The p35/CDK5 complex phosphorylates numerous substrates involved in:

Cytoskeletal proteins: Tau, MAP1B, neurofilaments

Synaptic proteins: Synaptic vesicles, NMDA/AMPA receptor subunits

Transcription factors: CREB, NF-κB, p53

Signal transduction: Various kinases and phosphatases

The activity of the p35/CDK5 complex is tightly regulated through multiple mechanisms, including protein synthesis, degradation, phosphorylation, and proteolytic cleavage. This complex regulation ensures proper temporal and spatial control of CDK5 activity during neuronal development and in the adult brain. [@fischer2017]

Neuronal Development

During CNS development, the p35/CDK5 complex plays essential roles in:

Neuronal migration: Phosphorylation of substrates that regulate cytoskeletal dynamics necessary for radial and tangential migration
Axon guidance: Modulation of growth cone dynamics and guidance cue responses
Synaptogenesis: Regulation of synaptic protein localization and assembly
Cell cycle exit: Contributing to the irreversible post-mitotic state of neurons

Mouse knockout studies demonstrate that CDK5R1 deletion results in perinatal lethality with severe cortical lamination defects, highlighting the essential nature of this gene during development. [@su2018]

Synaptic Plasticity and Memory

In the adult brain, p35/CDK5 continues to play crucial roles in synaptic function and plasticity:

Long-term potentiation (LTP): CDK5 activity is required for stable LTP, partly through phosphorylation of NMDA and AMPA receptor subunits
Long-term depression (LTD): CDK5 regulates endocytosis of AMPA receptors during LTD
Learning and memory: Conditional knockout of CDK5 in excitatory neurons enhances memory formation, while p25 overexpression impairs cognition

The role of CDK5 in memory consolidation is particularly interesting, as it appears to act as a negative regulator under certain conditions, with CDK5 activity increasing after learning to constrain memory strength—a potential mechanism to prevent overconsolidation. [@fischer2017] [@giese2015]

Cytoskeletal Regulation

p35/CDK5 phosphorylates multiple cytoskeletal proteins essential for neuronal structure and transport:

Tau: Phosphorylation at multiple sites (Ser202, Thr205, Ser396, etc.) regulates microtubule binding
MAP1B: Phosphorylation regulates microtubule dynamics during development
Neurofilaments: Phosphorylation maintains neurofilament stability and transport
Dynamin-1: Phosphorylation regulates synaptic vesicle endocytosis

Dysregulation of these phosphorylation events contributes to cytoskeletal disruption, transport deficits, and ultimately, neuronal dysfunction in neurodegeneration. [@shukla2019]

Role In Neurodegeneration

Alzheimer's Disease

The involvement of CDK5R1/CDK5 in AD is multifaceted and represents one of the most well-characterized pathogenic mechanisms:

p35 to p25 Cleavage

In AD brains, p35 is abnormally cleaved by calcium-activated calpains to generate the truncated p25 fragment. This cleavage is thought to occur as a result of:

Calcium dysregulation: AD-associated calcium dyshomeostasis activates calpains

Oxidative stress: Oxidative modifications to p35 may increase its susceptibility to cleavage

Age-related changes: Calpain activation increases with normal aging

The p25 fragment has a longer half-life than p35, leading to accumulation and prolonged CDK5 activation. Additionally, p25 lacks the membrane-targeting myristoylation site, resulting in mislocalized kinase activity throughout the neuron. [@generation2004] [@chen2018]

Tau Hyperphosphorylation

Hyperactive p25/CDK5 phosphorylates tau at multiple sites that promote its aggregation into neurofibrillary tangles:

Ser202/Thr205: AD-relevant phosphorylation sites found in early pretangles
Ser396: Critical for tangle formation
Thr231: conformational change facilitating aggregation

This phosphorylation disrupts tau's ability to bind microtubules and promotes its self-assembly into paired helical filaments. Importantly, p25/CDK5 can also phosphorylate kinases (GSK-3β) and inhibit phosphatases (PP2A) that further exacerbate tau pathology. [@cdk2004] [@zhang2021]

Synaptic Dysfunction

p25/CDK5 hyperactivity contributes to synaptic loss through:

AMPA receptor trafficking: Abnormal phosphorylation affects synaptic plasticity mechanisms

Presynaptic proteins: Impaired vesicle release and recycling

Dendritic spine morphology: Reduced spine density and altered spine shape

NMDA receptor dysfunction: Altered receptor trafficking and signaling

The synaptic effects of p25 accumulation occur early in disease and likely contribute to the cognitive decline that precedes overt neuron loss. [@cdka2004] [@fischer2017]

Parkinson's Disease

In PD, CDK5 participates in several pathogenic mechanisms:

LRRK2 Phosphorylation

CDK5 phosphorylates leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of familial PD:

CDK5 phosphorylates LRRK2 at Ser910 and Ser935, regulating its cytosolic localization
Pathogenic LRRK2 mutations may alter CDK5-mediated regulation
This interaction connects two major PD pathways

Dopaminergic Neuron Vulnerability

CDK5 activity is particularly high in dopaminergic neurons of the substantia nigra:

MPTP and other PD toxins increase CDK5 activity
CDK5 inhibition protects against toxin-induced dopaminergic death
p25 accumulation is observed in PD brains

Alpha-Synuclein Interplay

CDK5 can phosphorylate alpha-synuclein at Ser129, a modification found in Lewy bodies:

Phosphorylated alpha-synuclein shows enhanced aggregation
CDK5-mediated phosphorylation may link the two major proteinopathies in PD

These findings position CDK5 as a therapeutic target in PD, though the complexity of its physiological functions requires careful approach. [@cdkb2007] [@lrrk2009] [@liu2016] [@mendonca2020]

Amyotrophic Lateral Sclerosis

In ALS, CDK5 dysregulation contributes to motor neuron pathology:

TDP-43 phosphorylation: CDK5 can phosphorylate TDP-43, a major protein in ALS pathology

Cytoskeletal disruption: Enhanced phosphorylation of neurofilaments

Axonal transport deficits: Impaired organelle trafficking

Muscle denervation: Synaptic dysfunction at the neuromuscular junction

Motor neurons appear particularly vulnerable to CDK5 dysregulation due to their large size and dependence on cytoskeletal integrity. [@cdkc2010]

Other Neurodegenerative Conditions

Frontotemporal Dementia

In FTD and related tauopathies, CDK5-mediated tau phosphorylation contributes to pathology:

Elevated p25 levels in some FTD cases
Tau phosphorylation at CDK5 sites correlates with disease severity
Interaction with other FTD-linked proteins

Huntington's Disease

CDK5 is implicated in HD through:

Abnormal regulation in striatal neurons
Interaction with mutant huntingtin protein
Contribution to transcriptional dysregulation

Multiple Sclerosis

Emerging evidence suggests CDK5 involvement in demyelinating diseases:

Oligodendrocyte differentiation regulation
Myelin protein phosphorylation
Axonal degeneration mechanisms

Disease Associations And Translational Relevance

Therapeutic Strategies

Given the strong evidence for CDK5 dysregulation in neurodegeneration, several therapeutic approaches are being explored:

CDK5 Inhibitors

Roscovitine (Seliciclib): The most advanced CDK5 inhibitor, originally developed for cancer, shows neuroprotective effects in AD and PD models. Currently in clinical trials for various indications. [@dwyer2016] [@qu2019]

Alogliptin: A DPP-4 inhibitor with off-target CDK5 modulatory activity, approved for diabetes; being investigated for neurodegenerative applications

Specific p25 inhibitors: Targeting the p25/CDK5 complex specifically to avoid interfering with physiological p35/CDK5 function

Calpain Inhibitors

Since calpain-mediated p35 cleavage generates p25, calpain inhibitors represent an indirect approach:

MDL-28170: Shown to reduce p25 generation and protect neurons
Natural compounds: Certain flavonoids and polyphenols with calpain-inhibitory activity

p35-Targeting Approaches

Gene therapy: Viral delivery of p35 or its derivatives to restore proper CDK5 regulation

Peptide inhibitors: Cell-permeable peptides that block p25-CDK5 interaction

Allosteric modulators: Compounds that modulate the p35-CDK5 interface

Biomarker Potential

Changes in p35/p25 ratios or CDK5 activity may serve as biomarkers:

CSF p25 levels correlate with disease severity in some studies
Peripheral blood mononuclear cell CDK5 activity as a surrogate marker
Further validation needed for clinical implementation

Challenges in Therapeutic Development

Physiological functions: CDK5 has essential roles in learning, memory, and neuronal health

Cell-type specificity: Effects differ between neuronal subtypes

BBB penetration: Many CDK5 inhibitors have limited brain access

Narrow therapeutic window: Balance between efficacy and toxicity

Experimental Models And Methods

Genetic models: p35 knockout mice (lethal), p25 transgenic mice (AD-like pathology), conditional p25 mice (reversible phenotype) [@kanungo2015]

Viral vectors: AAV-mediated p25 expression to model neurodegeneration

Inhibitor studies: Roscovitine and derivatives in various disease models

Cell culture: Primary neurons, iPSC-derived neurons for mechanistic studies

Phosphoproteomics: Global mapping of CDK5 substrates in disease states

Research Gaps And Future Directions

Temporal dynamics: When does p25 accumulation begin relative to clinical symptoms?

Cell-type specificity: What makes certain neurons more vulnerable to p25/CDK5 dysregulation?

Biomarker validation: Can p25 or CDK5 activity serve as a clinical biomarker?

Combination therapies: How might CDK5-targeted approaches combine with anti-amyloid or anti-tau strategies?

Safety considerations: How can we preserve physiological CDK5 function while targeting pathological p25 activity?

References

[Lee et al., CDK5 in tau pathogenesis (2004)](https://pubmed.ncbi.nlm.nih.gov/14597658/)

[Patrick et al., p25 generation in AD brain (2004)](https://pubmed.ncbi.nlm.nih.gov/14749363/)

[Huang et al., CDK5 and synaptic plasticity (2004)](https://pubmed.ncbi.nlm.nih.gov/15162105/)

[Smith et al., CDK5 in PD models (2007)](https://pubmed.ncbi.nlm.nih.gov/17452840/)

[Greggio et al., LRRK2 phosphorylation by CDK5 (2009)](https://pubmed.ncbi.nlm.nih.gov/19794439/)

[Cruz et al., CDK5 in ALS (2010)](https://pubmed.ncbi.nlm.nih.gov/20665475/)

[Rack et al., CDK5 in Huntington's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19855041/)

[Alonso et al., CDK5 in frontotemporal dementia (2010)](https://pubmed.ncbi.nlm.nih.gov/20629637/)

[Zhang et al., CDK5-mediated tau phosphorylation (2021)](https://pubmed.ncbi.nlm.nih.gov/34104218/)

[Chen et al., Calpain-mediated p35 cleavage (2018)](https://pubmed.ncbi.nlm.nih.gov/30531792/)

[Qu et al., CDK5 inhibitors for AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31364171/)

[Fischer et al., CDK5/p35 signaling in synaptic plasticity (2017)](https://pubmed.ncbi.nlm.nih.gov/28647657/)

[Kanungo et al., p35 transgenic models (2015)](https://pubmed.ncbi.nlm.nih.gov/25872432/)

[Liu et al., CDK5 in PD pathogenesis (2016)](https://pubmed.ncbi.nlm.nih.gov/27550158/)

[Mendonca et al., CDK5 and alpha-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32621397/)

[Su et al., CDK5 substrates in neuronal development (2018)](https://pubmed.ncbi.nlm.nih.gov/29544312/)

[Dwyer et al., Roscovitine in AD models (2016)](https://pubmed.ncbi.nlm.nih.gov/27185314/)

[Giese et al., Memory consolidation and CDK5 (2015)](https://pubmed.ncbi.nlm.nih.gov/26120963/)

[Shukla et al., CDK5 in cytoskeletal dynamics (2019)](https://pubmed.ncbi.nlm.nih.gov/31049873/)

[Petralla et al., CDK5 and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32791964/)

📖 View canonical wiki page →

Related Entities

CDK5R1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cdk5r1
kg_node_id	CDK5R1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9779459ee251
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cdk5r1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CDK5R1 Gene

CDK5R1 Gene

Introduction

CDK5R1 Gene

Introduction

Gene And Protein Context

Molecular Functions In The Nervous System

CDK5 Activation and Regulation

Neuronal Development

Synaptic Plasticity and Memory

Cytoskeletal Regulation

Role In Neurodegeneration

Alzheimer's Disease

p35 to p25 Cleavage

Tau Hyperphosphorylation

Synaptic Dysfunction

Parkinson's Disease

LRRK2 Phosphorylation

Dopaminergic Neuron Vulnerability

Alpha-Synuclein Interplay

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Frontotemporal Dementia

Huntington's Disease

Multiple Sclerosis

Disease Associations And Translational Relevance

Therapeutic Strategies

CDK5 Inhibitors

Calpain Inhibitors

p35-Targeting Approaches

Biomarker Potential

Challenges in Therapeutic Development

Experimental Models And Methods

Research Gaps And Future Directions

See Also

References

💬 Discussion